Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2566)

VOLUNTARY ANNOUNCEMENT MARKETING APPLICATION FOR JIKEQIN® APPROVED BY NMPA

This announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development.

The board of directors (the "**Board**") of the Company is pleased to announce that the marketing application for Jikeqin 吉可親® (the "**Product**"), developed by the Group has been accepted by the National Medical Products Administration of the People's Republic of China ("**NMPA**").

The Product is a biosimilar of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide developed by the Group. It is filed under Category 3.3 of biological drug registration and is intended for weight management in individuals with obesity or overweight. Jikeqin 吉可親® mimics the physiological effects of endogenous GLP-1 hormone, exerting multiple mechanisms including promoting insulin secretion, inhibiting glucagon release, suppressing appetite, and delaying gastric emptying, thereby improving blood sugar control and achieving weight management. In the completed Phase III clinical trial, Jikeqin 吉可親® was evaluated in a randomized, open-label, active-controlled, parallel-designed clinical equivalence study in subjects with obesity. The study results demonstrated that it is clinically equivalent to the reference drug in terms of the primary efficacy indicators (the percent change in body weight from baseline after 44 weeks of treatment) and safety profile, exhibiting favorable efficacy and tolerability.

The Company has received a drug clinical trial approval notice issued by the National Medical Products Administration in January 2024 for Jikeqin 吉可親®, and has completed the enrollment of all subjects of the phase III clinical trial in December 2024. The Company has now completed the trial, and the relevant application materials for market approval have been submitted to the Center for Drug Evaluation of NMPA for review.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, February 25, 2026

As at the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.